ONCY
Oncolytics Biotech Inc
$0.90
+0.00 (+0.00%)
At close · Jul 2
Market Cap
$107.31M
Shares
119,354,067
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$0.90
Open$0.92
Day$0.87–0.94
52W$0.71–1.51
Avg vol 30d1.3M
Short int7.1M · 6.0% float · 3.7d
Short vol63%
Last earningsMar 31, 2025
DataJan 2020–Jul 2026
Filing10-Q · May 14
Equibles Rating
blended score · not investment advice
Overall
Neutral
Technical · trend & momentum
Neutral
◦
50 / 200-day cross
no cross
−
Price vs 200-day avg
−12% below
◦
Price vs 50-day avg
−1% below
◦
RSI (14)
49 · neutral
+
MACD trend
positive
◦
52-week position
24% · mid-range
Sentiment · smart money
Bearish
◦
Trend (MA cross)
50d $1 › 200d $1 — 200d above 50d
−
Institutional flow
-7% holders QoQ · +15 funds added
◦
Insider flow
No net insider activity over 90 days
−
Short interest
5.97% of float · ▲ +3.2% MoM · 3.7 days cover
◦
Volume signal
Volume near normal
◦
Institution breadth
57 holders — mid 3-yr range
Fundamentals
Fair
◦
EPS growth
0% Y/Y
−
Free cash flow
$-20.1M
+
Balance sheet
net cash $5.2M
Blended from price, positioning & fundamentals · daily-close · not investment advice.
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 14, 2026
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
no cross
Neutral
Price vs 200-day avg
−12% below
Bearish
Price vs 50-day avg
−1% below
Neutral
RSI (14)
49 · neutral
Neutral
MACD trend
positive
Bullish
52-week position
24% · mid-range
Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross)
No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow
Distributing
-7% holders QoQ · +15 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
5.97% of float · ▲ +3.2% MoM · 3.7 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
57 holders — mid 3-yr range
Price context
position in its 52-week range
52-wk low $1
Now $1 · 24%
52-wk high $2
vs 200-day avg -12%
vs 50-day avg -1%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ONCY
this stock
Oncolytics Biotech Inc
|
$107.31M | +3.4% | — | — | 6.0% |
|
AKTX
Akari Therapeutics Plc
|
$953.21B | -9.9% | — | — | 0.0% |
|
ONC
BeOne Medicines Ltd.
|
$470.30B | -2.0% | +22179.2% | 957.1 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$134.02B | +16.5% | +46.2% | 31.3 | 1.8% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$69.80B | -15.1% | +20.8% | 16.3 | 3.2% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ONCY | -2.2% | +2.3% | -9.1% | -5.3% | +3.5% |
| SPY | +1.4% | -1.3% | +8.0% | -0.3% | +9.2% |
| vs SPY | -3.6% | +3.5% | -17.1% | -5.0% | -5.8% |